Methods of preparing oral controlled release formulations
The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls rapidly at the end of the dosing interval.
1. A method of preparing an oral controlled release once-a-day formulation comprising:
coating a controlled release substrate comprising a copolymer of acrylic and methacrylic esters having a molar ratio of ammonium groups to the remaining neutral (meth)acrylic esters of 1:20 or a copolymer of acrylic and methacrylic esters having a molar ratio of ammonium groups to the remaining neutral (meth)acrylic esters of 1:40 and a first portion of methylphenidate hydrochloride with an enteric coating, and
overcoating the enteric coating with an immediate release coating comprising a second portion of methylphenidate hydrochloride,
wherein the enteric coating comprises a methacrylic acid copolymer which does not swell at about pH<5.7 and is soluble at about pH>6 in an amount that would delay release of the first portion of methylphenidate from the controlled release substrate until the plasma concentration of methylphenidate provided by the second portion of methylphenidate falls from its peak.
2. The method of claim 1 , wherein the controlled release substrate comprises the copolymer of acrylic and methacrylic esters having a molar ratio of ammonium groups to the remaining neutral (meth)acrylic esters of 1:20.
3. The method of claim 1 , wherein the formulation is a multi-layered release formulation.
4. A method of preparing an oral controlled release once-a-day formulation comprising:
coating a controlled release substrate comprising a first portion of methylphenidate hydrochloride with an enteric coating, and
overcoating the enteric coating with an immediate release coating comprising a second portion of methylphenidate hydrochloride,
wherein the enteric coating comprises a methacrylic acid copolymer which does not swell at about pH<5.7 and is soluble at about pH>6 in an amount that would delay release of the first portion of methylphenidate from the controlled release substrate until the plasma concentration of methylphenidate provided by the second portion of methylphenidate falls from its peak, and provide a peak in methylphenidate plasma concentration at about 8 hours after oral administration under fed conditions and effective methylphenidate plasma concentrations for about 12 hours after said oral administration.
5. The method of claim 4 , wherein the controlled release substrate comprises a copolymer of acrylic and methacrylic esters having a molar ratio of ammonium groups to the remaining neutral (meth)acrylic esters of 1:20.
6. The method of claim 4 , wherein the formulation is a multi-layered release formulation.
7. The method of claim 1 , wherein the controlled release substrate comprises the copolymer of acrylic and methacrylic esters having a molar ratio of ammonium groups to the remaining neutral (meth)acrylic esters of 1:40.
8. The method of claim 4 , wherein the controlled release substrate comprises a copolymer of acrylic and methacrylic esters having a molar ratio of ammonium groups to the remaining neutral (meth)acrylic esters of 1:40.